Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
4
×
national blog main
boston blog main
boston top stories
fda
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
biotech
parkinson's disease
san francisco blog main
san francisco top stories
abbvie
acorda therapeutics
akcea therapeutics
alder biopharmaceuticals
alnylam pharmaceuticals
amgen
ampyra
andrew fire
apokyn
apomorphine
bial
boston
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
chronic migraine
craig mello
dalfampridine
david rind
detroit blog main
detroit top stories
drug development
duopa
eli lilly
episodic migraine
What
fda
4
×
gets
4
×
drug
nod
approved
disease
new
parkinson’s
patients
acorda
add
afternoon
alnylam
alnylam’s
amgen
approval
called
candidates
carbidopa
class
combination
control
cope
daily
developed
episodes
experience
friday
head
help
history
landmark
late
levodopa
looms
making
meant
medication
medications
medicine
Language
unset
Current search:
fda
×
" life sciences "
×
gets
×
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines